“Generic drugmakers are under intense pressure to cut their costs and some will do that by cutting quality,” said David Ridley of Duke University, who studies the pharmaceutical industry.
Nearly 2,000 drug manufacturing plants overdue for FDA inspections after COVID delays, AP finds
→
“The FDA is not getting its job done in terms of drug quality assurance inspections abroad,” said David Ridley of Duke University and co-author of a recent paper tracking the downturn in inspections.
After recalls and infections, experts say safer eyedrops will require new FDA regulations
→
